Please login to the form below

Not currently logged in


This page shows the latest F-Star news and features for those working in and with pharma, biotech and healthcare.

Cancer disruptor F Star names next CEO

Cancer disruptor F Star names next CEO

Dr Eliot Forster takes reins from Dr John Haurum. UK-based biotech F-star has named Dr Eliot Forster as its new chief executive. ... I believe that F-star’s first-in-class molecules bring together in a single form, the full power of IO and combinations.

Latest news

  • BMS taps F-star Alpha for immuno-oncology drug BMS taps F-star Alpha for immuno-oncology drug

    Drug in development for breast and stomach cancers. Bristol-Myers Squibb (BMS) has hatched a plan to buy Austrian biotech F-star Alpha in order to claim rights to FS102, a ... F-star has its headquarters in Vienna but runs its research operations out of

  • f-star wins €15m investment

    Antibody specialist f-star secures funding from existing investors and adds new members to its supervisory board. ... f-star, a company developing antibody-based products, has secured 15m of new financing.

  • Survival strategy

    During November and December 2010 there were five Big Pharma discovery deals involving Boehringer Ingelheim (with f-star), S-A (with Avila Therapeutics), Pfizer (with Phylogica), Tanabe Research Laboratories (with Anaphore) ... f-star/Boehringer

  • PM Society Awards 2005

    These days you're lucky if you can give them a three-star hotel and a f ing biro. ... He also issued a thinly-veiled warning to any entrants who had been honoured with a highly commended': Congratulations and all that but stay in your f ing seat.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast /   gastric cancer.

  • Pharma deals during October 2014 Pharma deals during October 2014

    A major feature throughout 2014 has been the deployment of options. This month is no exception with Bristol-Myers Squibb (BMS) securing an exclusive option to acquire F-star Alpha gaining

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....